Improved survival with bevacizumab in advanced cervical cancer.

BACKGROUND Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent activity in previously treated, recurrent disease. Most patients in whom recurrent cervical cancer develops have previously received cisplatin with radiation therapy, which reduces the effectiveness of cisplatin at the time of recurrence. We evaluated the effectiveness of bevacizumab and nonplatinum combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer. METHODS Using a 2-by-2 factorial design, we randomly assigned 452 patients to chemotherapy with or without bevacizumab at a dose of 15 mg per kilogram of body weight. Chemotherapy consisted of cisplatin at a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 175 mg per square meter or topotecan at a dose of 0.75 mg per square meter on days 1 to 3, plus paclitaxel at a dose of 175 mg per square meter on day 1. Cycles were repeated every 21 days until disease progression, the development of unacceptable toxic effects, or a complete response was documented. The primary end point was overall survival; a reduction of 30% in the hazard ratio for death was considered clinically important. RESULTS Groups were well balanced with respect to age, histologic findings, performance status, previous use or nonuse of a radiosensitizing platinum agent, and disease status. Topotecan-paclitaxel was not superior to cisplatin-paclitaxel (hazard ratio for death, 1.20). With the data for the two chemotherapy regimens combined, the addition of bevacizumab to chemotherapy was associated with increased overall survival (17.0 months vs. 13.3 months; hazard ratio for death, 0.71; 98% confidence interval, 0.54 to 0.95; P=0.004 in a one-sided test) and higher response rates (48% vs. 36%, P=0.008). Bevacizumab, as compared with chemotherapy alone, was associated with an increased incidence of hypertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 1%), and gastrointestinal fistulas of grade 3 or higher (3% vs. 0%). CONCLUSIONS The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).

[1]  A. Troxel,et al.  Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. , 2004, Gynecologic oncology.

[2]  P. Disaia,et al.  A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. , 1989, Gynecologic oncology.

[3]  J. Rader,et al.  Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Thigpen Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study , 2010 .

[5]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[6]  D.,et al.  Regression Models and Life-Tables , 2022 .

[7]  N. Park,et al.  Expression of Vascular Endothelial Growth Factor and Hypoxia Inducible Factor‐1α in Cervical Neoplasia , 2009, Annals of the New York Academy of Sciences.

[8]  J. Bodily,et al.  Tumor and Stem Cell Biology Human Papillomavirus E 7 Enhances Hypoxia-Inducible Factor 1 – Mediated Transcription by Inhibiting Binding of Histone Deacetylases , 2011 .

[9]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[10]  B. Monk,et al.  The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. , 2010, Clinical advances in hematology & oncology : H&O.

[11]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[12]  B. Monk,et al.  Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. , 2000, Gynecologic oncology.

[13]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[14]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[15]  B. Monk,et al.  Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study , 2006 .

[16]  B. Monk,et al.  Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Monk,et al.  Beyond Platinum for Metastatic and Recurrent Carcinoma of the Cervix , 2009, Oncology Research and Treatment.

[18]  Mark R. Green,et al.  Synergistic interaction between topotecan and microtubule-interfering agents , 2001, Cancer Chemotherapy and Pharmacology.

[19]  P. Disaia,et al.  Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[21]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[22]  B. Monk,et al.  Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Diggle Analysis of Longitudinal Data , 1995 .

[24]  B. Monk,et al.  Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. O'fallon,et al.  Stopping when the experimental regimen does not appear to help. , 1994, Statistics in medicine.

[26]  A. Le,et al.  Overexpression of Human Papillomavirus Type 16 Oncoproteins Enhances Hypoxia-Inducible Factor 1α Protein Accumulation and Vascular Endothelial Growth Factor Expression in Human Cervical Carcinoma Cells , 2007, Clinical Cancer Research.

[27]  D. Mutch,et al.  Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  B. Monk,et al.  Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. , 2010, Gynecologic oncology.

[29]  P. Disaia,et al.  INVASIVE CERVICAL CANCER , 1981 .

[30]  K. Tewari,et al.  Chapter 3 – Invasive Cervical Cancer , 2012 .

[31]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[32]  P. Disaia,et al.  A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  B. Monk,et al.  Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. , 2009, Seminars in oncology.

[34]  B. Monk,et al.  Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer , 2005, Current oncology reports.

[35]  D. Cella,et al.  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  I. Lascombe,et al.  The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism. , 2007, Experimental cell research.

[37]  PRO: Patients With Metastatic/Recurrent Cervical Cancer Should Be Treated With Cisplatin Plus Paclitaxel , 2010 .